Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON), a rare disease-focused pharmaceutical company, announced executive participation in three investor conferences in May and June 2026.

Events include the B. Riley Securities and Craig-Hallum conferences without presentations, and a Jefferies Global Healthcare Conference appearance with a webcast on June 4, 2026.

News Market Reaction – ETON

+3.74%

+3.74% Session close to close

In the May 13 session, ETON gained 3.74%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows:

• The 26^th Annual B. Riley Securities Investor Conference
  Date: Wednesday, May 20, 2026
  Location: The Ritz-Carlton, Marina Del Rey, California

• The 23^rd Annual Craig-Hallum Institutional Investor Conference
  Date: Thursday, May 28, 2026
  Location: Depot Renaissance Hotel Minneapolis, Minnesota

• Jefferies Global Healthcare Conference
  Date: Thursday, June 4, 2026 at 9:55-10:25AM ET
  Location: New York, New York
  Webcast: Click Here

There are no presentations for the B. Riley Securities and Craig-Hallum conferences.

About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI™, INCRELEX^®, ALKINDI SPRINKLE^®, DESMODA™, GALZIN^®, HEMANGEOL^®, PKU GOLIKE^®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia^®, ET-700, ET-800 and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

Which investor conferences will Eton Pharmaceuticals (NASDAQ: ETON) attend in May and June 2026?

Eton Pharmaceuticals will attend three investor conferences in May and June 2026. According to Eton, these are the B. Riley Securities, Craig-Hallum Institutional, and Jefferies Global Healthcare conferences, offering multiple touchpoints for engagement with institutional and healthcare-focused investors.

When and where is Eton Pharmaceuticals presenting at the Jefferies Global Healthcare Conference 2026?

Eton Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on Thursday, June 4, 2026. According to Eton, management is scheduled from 9:55 to 10:25 AM ET in New York, providing a dedicated time window for investors to hear company updates.

Will Eton Pharmaceuticals (ETON) have webcast access for its June 4, 2026 Jefferies conference appearance?

Yes, Eton Pharmaceuticals will provide a webcast for its Jefferies Global Healthcare Conference appearance. According to Eton, the June 4, 2026 session from 9:55 to 10:25 AM ET in New York will be accessible online for remote investors.

Is Eton Pharmaceuticals presenting at the 26th Annual B. Riley Securities Investor Conference in May 2026?

Eton Pharmaceuticals management will attend the 26th Annual B. Riley Securities Investor Conference on May 20, 2026. According to Eton, there will be no formal presentation at this event, implying participation will likely focus on meetings and informal investor interactions.

What is Eton Pharmaceuticals doing at the 23rd Annual Craig-Hallum Institutional Investor Conference 2026?

Eton Pharmaceuticals will participate in the 23rd Annual Craig-Hallum Institutional Investor Conference on May 28, 2026. According to Eton, there are no scheduled presentations, suggesting the company’s involvement may center on one-on-one or small group meetings with institutional investors.

What type of company is Eton Pharmaceuticals (NASDAQ: ETON) and why is it attending these conferences?

Eton Pharmaceuticals is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. According to Eton, participation in these May and June 2026 investor conferences helps showcase its rare disease strategy and engage with current and potential shareholders.